Access to medications for cardiovascular diseases in low- and middle-income countries

Circulation

Volumn 133, Issue 21, 2016, Pages 2076-2085

  Wirtz, Veronika J ^a   Kaplan, Warren A ^a   Kwan, Gene F ^b   Laing, Richard O ^a  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular diseases; delivery of health care; drug therapy; essential drugs; health services accessibility; medication adherence; policy

Indexed keywords

CARDIOVASCULAR AGENT; GENERIC DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG COST; DRUG QUALITY; DRUG USE; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; LOWEST INCOME GROUP; MEDICATION COMPLIANCE; PATENT; PRIORITY JOURNAL; SOCIOECONOMICS; SYSTEMATIC REVIEW (TOPIC); CARDIOVASCULAR DISEASES; DEVELOPING COUNTRY; ECONOMICS; POVERTY;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; POVERTY;

EID: 84969962021     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.008722     Document Type: Article

References (73)

1. Lu Y, Hernandez P, Abegunde D, Edejer T, Medicines expenditure. World Medicines Situation 2011 2011 Accessed April 30, 2016 Geneva, Switzerland World Health Organization. http://apps.who.int/medicinedocs/documents/s18767en/s18767en.pdf. WHO/EMP/MIE/2011.2.6
2. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, Van Damme W, Access to medicines from a health system perspective. Health Policy Plan 2013 28 692 704. doi: 10.1093/heapol/czs108
3. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M, The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation 2014 129 1493 1501. doi: 10.1161/CIRCULATIONAHA.113.004046
4. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 385 117 171
5. Global Status Report on Noncommunicable Diseases 2010. 2011 Geneva, Switzerland World Health Organization
6. Ezzati M, Riboli E, Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 2013 369 954 964. doi: 10.1056/NEJMra1203528
7. Seckeler MD, Hoke TR, The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol 2011 3 67 84. doi: 10.2147/CLEP.S12977
8. Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 386 743 800
9. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K, The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012 172 1386 1394. doi: 10.1001/archinternmed.2012.3310
10. Kwan GF, Jean-Baptiste W, Cleophat P, Leandre F, Louine M, Luma M, Benjamin EJ, Mukherjee JS, Bukhman G, Hirschhorn LR, Descriptive epidemiology and short-Term outcomes of heart failure hospitalisation in rural Haiti. Heart 2016 102 140 146. doi: 10.1136/heartjnl-2015-308451
11. Kwan GF, Bukhman AK, Miller AC, Ngoga G, Mucumbitsi J, Bavuma C, Dusabeyezu S, Rich ML, Mutabazi F, Mutumbira C, Ngiruwera JP, Amoroso C, Ball E, Fraser HS, Hirschhorn LR, Farmer P, Rusingiza E, Bukhman G, A simplified echocardiographic strategy for heart failure diagnosis and management within an integrated noncommunicable disease clinic at district hospital level for sub-Saharan Africa. JACC Heart Fail 2013 1 230 236. doi: 10.1016/j.jchf.2013.03.006
12. Adherence to Long-Term Therapies: Evidence for Action 2003 Geneva, Switzerland World Health Organization
13. Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans D, Jha P, Mills A, Musgrove P, Cardiovascular disease. Disease Control Priority in Developing Countries 2006 2nd ed Washington, DC World Bank chap 33
14. Fuster V, Kelly BB, Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Improve Global Health 2010 Washington, DC Institute of Medicine
15. Webster R, Rodgers A, Kaplan W, Wirtz VJ, Mantel-Teeuwisse, Stolk P, Duthey B, Laing R, Ischaemic heart disease: background paper 6.3. Priority Medicines for Europe and the World Report 2013 2013 Geneva, Switzerland World Health Organization. http://www.who.int/entity/medicines/areas/priority-medicines/BP6-3IHD.pdf?ua=1
16. Scaling Up Action Against Noncommunicable Diseases: How Much Will It Cost? 2011 Geneva, Switzerland World Health Organization
17. Best Buy Intervention for the Prevention and Treatment of CVD 2010 Geneva, Switzerland World Health Organization
18. Ortegón M, Lim S, Chisholm D, Mendis S, Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 2012 344 e607
19. Irlam J, Mayosi BM, Engel M, Gaziano TA, Primary prevention of acute rheumatic fever and rheumatic heart disease with penicillin in South African children with pharyngitis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 2013 6 343 351. doi: 10.1161/CIRCOUTCOMES.111.000032
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013 128 1810 1852. doi: 10.1161/CIR.0b013e31829e8807
21. Ibrahim MM, Damasceno A, Hypertension in developing countries. Lancet 2012 380 611 619. doi: 10.1016/S0140-6736(12)60861-7
22. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B, WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005 83 820 829. doi: /S0042-96862005001100011
23. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, Prospective Urban Rural Epidemiology (PURE) Study Investigators Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011 378 1231 1243. doi: 10.1016/S0140-6736(11)61215-4
24. Di Cesare M, Khang YH, Asaria P, Blakely T, Cowan MJ, Farzadfar F, Guerrero R, Ikeda N, Kyobutungi C, Msyamboza KP, Oum S, Lynch JW, Marmot MG, Ezzati M, Lancet NCD Action Group Inequalities in non-communicable diseases and effective responses. Lancet 2013 381 585 597. doi: 10.1016/S0140-6736(12)61851-0
25. Penchansky R, Thomas JW, The concept of access: definition and relationship to consumer satisfaction. Med Care 1981 19 127 140
26. Access to Medicines and Health Technologies 2012 Washington, DC Management Sciences for Health
27. Frost L, Reich M, The access framework. Access: How Do Good Technologies Get to Poor People in Poor Countries? 2008 Cambridge, MA Harvard University Press chap 2
28. World Health Organization Definition of SSFFC. Accessed April 30, 2016. http://www.who.int/medicines/regulation/ssffc/definitions/en/.
29. World Health Organization WHO Expert Committee. Accessed April 30, 2016. http://www.who.int/selection-medicines/committees/en/.
30. Moucheraud C, Wirtz VJ, Reich MR, Evaluating the quality and use of economic data in decisions about essential medicines. Bull World Health Organ 2015 93 693 699. doi: 10.2471/BLT.14.149914
31. World Health Organization WHO Model List of Essential Medicines. Accessed April 30, 2016. http://www.who.int/medicines/publications/essentialmedicines/en/.
32. Twagirumukiza M, Annemans L, Kips JG, Bienvenu E, Van Bortel LM, Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's Model List of Essential Medicines. Trop Med Int Health 2010 15 350 361. doi: 10.1111/j.1365-3156.2009.02453.x.
33. World Health Organization Raised cholesterol. Accessed January 23, 2016. http://www.who.int/gho/ncd/risk-factors/cholesterol-text/en/.
34. World Health Organization/Health Action International Medicine Prices, Availability, Affordability and Price Components 2008 Accessed April 30, 2016 2nd ed Geneva, Switzerland World Health Organization. http://www.haiweb.org/medicineprices/.
35. Van Mourik MS, Cameron A, Ewen M, Laing RO, Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010 10 25. doi: 10.1186/1471-2261-10-25
36. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO, Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011 89 412 421. doi: 10.2471/BLT.10.084327
37. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R, Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009 373 240 249. doi: 10.1016/S0140-6736(08)61762-6
38. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, Wei L, Mony P, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear SA, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Kazmi K, Rahman O, Rosengren A, Monsef N, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Temizhan A, Dagenais G, Gafni A, Yusuf S, PURE Study Investigators Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2016 387 61 69. doi: 10.1016/S0140-6736(15)00469-9
39. US Food and Drug Administration Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Accessed May 20 2014. http://www.accessdata.fda.gov/scripts/Cder/ob/default.cfm
40. European Patent Office Espacenet: patent search. Accessed April 30, 2016. http://worldwide.espacenet.com/?locale=en-EP.
41. Lucia Luiza V, Chaves LA, Silva RM, Emmerick IM, Chaves GC, Fonseca de Araújo S, Moraes EL, Oxman AD, The effect of direct payment policies on people's use of medicines. Cochrane Collaboration 2015 5 CD0070172
42. Bleich SN, Cutler DM, Adams AS, Lozano R, Murray CJ, Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study. BMJ 2007 335 875. doi: 10.1136/bmj.39350.617616.BE.
43. Maimaris W, Paty J, Perel P, Legido-Quigley H, Balabanova D, Nieuwlaat R, McKee M, The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med 2013 10 e1001490. doi: 10.1371/journal.pmed.1001490
44. Callen M, Gulzar S, Hasanain A, Khan Y, The political economy of public sector absence: experimental evidence from Pakistan. 2014 Accessed April 30, 2016. https://www.povertyactionlab.org/publication/political-economy-public-employee-Absence-experimental-evidence-pakistan. Working paper
45. Chaudhury N, Hammer J, Kremer M, Muralidharan K, Rogers FH, Missing in action: teacher and health worker absence in developing countries. J Econ Perspect 2006 20 91 116
46. Ambaw AD, Alemie GA, WYohannes SM, Mengesha ZB, Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health 2012 12 282. doi: 10.1186/1471-2458-12-282
47. Vialle-Valentin CE, Serumaga B, Wagner AK, Ross-Degnan D, Evidence on access to medicines for chronic diseases from household surveys in five low- And middle-income countries. Health Policy Plan 2015 30 1044 1052. doi: 10.1093/heapol/czu107
48. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, Nieuwlaat R, Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-Analysis of qualitative and quantitative studies. PLoS One 2014 9 e84238. doi: 10.1371/journal.pone.0084238
49. Manyemba J, Mayosi BM, Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev 2002 CD002227
50. Padmavati S, Gupta V, Prakash K, Sharma KB, Penicillin for rheumatic fever prophylaxis 3-weekly or 4-weekly schedule? J Assoc Physicians India 1987 35 753 755
51. Khatib R, Schwalm JD, Yusuf S, Haynes RB, McKee M, Khan M, Nieuwlaat R, Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-Analysis of qualitative and quantitative studies. PLoS One 2014 9 e84238. doi: 10.1371/journal.pone.0084238
52. Wald NJ, Law MR, A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 326 1419. doi: 10.1136/bmj.326.7404.1419
53. Kaplan W, Laing R, Priority Medicines for Europe and the World 2004 2004 Geneva, Switzerland World Health Organization
54. Neal B, Kaplan W, Laing R, Secondary prevention of cardiovascular disease: fixed dose combinations: a research agenda for the European Union: background paper. Priority Medicines for Europe and the World 2004 Accessed April 30, 2016 Geneva, Switzerland World Health Organization; http://archives.who.int/prioritymeds/report/background/cardiovascular.doc
55. India Polycap Study (TIPS) Effects of a polypill (Polycap) on risk factors in middle-Aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009 373 1341 1351
56. UMPIRE Collaborative Group Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013 310 918 929
57. Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S, The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010 122 2078 2088. doi: 10.1161/CIRCULATIONAHA.109.873232
58. Kaplan W, Wirtz VJ, Mantel-Teeuwisse Stolk P, Duthey B, Laing R, Priority Medicines for Europe and the World 2013 2013 Geneva, Switzerland World Health Organization
59. Deleted in proof
60. Institute of Medicine Countering the Problem of Falsified and Substandard Drugs 2013 Washington Institute of Medicine
61. Twagirumukiza M, Cosijns A, Pringels E, Remon JP, Vervaet C, Van Bortel L, Influence of tropical climate conditions on the quality of antihypertensive drugs from Rwandan pharmacies. Am J Trop Med Hyg 2009 81 776 781. doi: 10.4269/ajtmh.2009.09-0109. Accessed April 30, 2016
62. National Collegiate Inventors and Innovator Alliance Global innovation initiative. Fall 2010 Accessed April 30, 2016 4. http://nciia.com/sites/default/files/fall%202010.pdf
63. Sproxil About Sproxil TM . http://www.sproxil.com/blog/.
64. Intellectual Property India The Patents Act 1970: Chapter II: Inventions not patentable, Section 3, What are not inventions. Accessed April 30, 2016. http://ipindia.nic.in/ipr/patent/eVersion-ActRules/sections/ps3.html
65. Carrin G, Mathauer I, Xu K, Evans DB, Universal coverage of health services: tailoring its implementation. Bull World Health Organ 2008 86 857 863
66. World Health Organization, World Bank Tracking Universal Health Coverage: First Global Monitoring Report 2015 Geneva, Switzerland World Health Organization
67. Regulatory Affairs Professional Society New fixed-dose combination drugs now eligible for 5 years of exclusivity, FDA says. Accessed April 30, 2016. http://www.raps.org/Regulatory-Focus/News/2014/10/10/20544/New-Fixed-Dose-Combination-Drugs-Now-Eligible-for-5-Years-of-Exclusivity-FDA-Says/#sthash.wTysWyhG.dpuf
68. Hyden MD, Racit EP, Accessed April 30, 2016. European filing strategies on the eve of the unitary patent: EPO practice: full disclosure. http://www.finnegan.com/files/upload/Newsletters/Full-Disclosure/2013/March/FullDisclosure-Mar13-4.html
69. Institute for Health Metrics and Evaluation Financing Global Health 2012: The End of a Golden Age 2013 Seattle, WA University of Washington: Institute for Health Metrics and Evaluation
70. Scaling up Against Non-Communicable Diseases: How Much Will it Cost? 2011 Geneva, Switzerland World Health Organization
71. World Health Organization: Global Action Plan for the Prevention and Control of NCDs 2013-2020 2013 Geneva, Switzerland World Health Organization
72. Robertson J, Macé C, Forte G, de Joncheere K, Beran D, Medicines availability for non-communicable diseases: the case for standardized monitoring. Global Health 2015 11 18. doi: 10.1186/s12992-015-0105-0
73. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T, Lancet NCD Action Group Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet 2013 381 680 689. doi: 10.1016/S0140-6736(12)62128-X.